Challenges and strategies for identifying biomarkers for colorectal cancer

摘要

Since biologic therapies became a routine in the clinical practice of colorectal cancer (CRC), they have been shown to improve survival and have provided a new avenue for predictive biomarker research with the goal of improving outcomes. The targeted nature of these therapies has provided opportunities to propose and interrogate biomarkers related to the respective agents' mechanisms of action. KRAS mutation is currently the most recognized molecular predictive marker in CRC, predicting efficacy of anti-EGF receptor (anti-EGFR) antibodies.